Key Morningstar Metrics for Novo Nordisk
- : DKK 275Fair Value Estimate
- : ★★★Morningstar Rating
- : WideMorningstar Economic Moat Rating
- : HighMorningstar Uncertainty Rating
What We Thought of Novo Nordisk’s Earnings
Novo NOVO B reported 6% top-line growth and a 3% operating profit decline in the third quarter. Management raised full-year guidance to flat sales and operating profit at the midpoint at constant currencies (from a 3% decline at the midpoint). Shares closed 6% higher in Denmark on Nov. 4.
Why it matters: Given Lilly’s overall GLP-1 market share gains and stronger data for its portfolio and pipeline, the market was relieved to see that Novo pulled further away from the sales declines it saw late in 2025 and in early 2026, with two quarters of positive growth in a row.
- In GLP-1 obesity (22% growth at constant currencies), continued strong uptake of the Wegovy pill and the start of Medicare obesity drug coverage in July supported US growth despite lower prices, and the international Wegovy pill launch is poised to move faster in 2027 than we had expected.
- In GLP-1 diabetes (7% decline), we see temporary stability in pricing but continued share loss to Lilly’s Mounjaro. While the Ozempic pill rebranding (from Rybelsus) is benefiting US sales, we expect strong competition from Lilly’s Foundayo in 2027.
The bottom line: We’re maintaining our DKK 275/USD 42 fair value estimates for wide-moat Novo Nordisk. Our updated 2026 forecast implies a 2.7% year-over-year decline in sales in the fourth quarter, partly due to adjustments that benefited the prior-year quarter and generic competition in some markets.
- We think shares look fairly valued at recent prices. While there are several pushes and pulls that are making it difficult to call whether Novo will report growth or declines, we now model relatively flat sales for 2026 and 2027, with potential single-digit growth resuming in 2028.
- Novo needs to prove that it not only can innovate beyond semaglutide but also out-innovate peers, led by Lilly. While cagrisema is poised to launch in 2027, we’re skeptical about its commercial prospects based on multiple trial readouts, including head-to-head studies against Zepbound.

